Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking method to diabetes management. These innovative drugs work by mimicking the physiological actions of GLP-1, a hormone released by the gut in response to meals. By triggering GLP-1 receptors in the pancreas, these substances enhance insulin production and reduce glucag

The burgeoning landscape of emerging treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting substantial weight reduction – they exhibit intriguing differences i